Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BridgeBio Pharma, Inc.
< Previous
1
2
3
Next >
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
September 17, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
September 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
September 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
August 30, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
August 29, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in September Investor Events
August 28, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
August 26, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
August 19, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 08, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
August 01, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
July 23, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
June 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
June 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
June 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
June 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
May 29, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
May 24, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
May 14, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
May 13, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
May 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
May 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
April 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.